$VECT News
Last published 2mo ago
- 2mo agoVECTWells Fargo 21st Annual Healthcare Conference - VECTIVBIO HOLDING AGEarnings Call TranscriptsAwesome. Thank you very much for joining us again for the session with Ironwood management team. My name is Mohit Bansal and I'm joined by Tom McCourt, the CEO of the company, and Tammy Gaskins, the chief commercial offi
- 3mo agoVECTIronwood Pharmaceuticals Q2 2026 Investor Update Conference Call - VECTIVBIO HOLDING AGEarnings Call TranscriptsMy name is Ian, and I will be your conference operator today. At this time, I would like to welcome everyone to the Ironwood Pharmaceuticals Q2 2026 Investor Update Conference Call. All lines have been placed on mute to
- 6mo agoVECTIronwood Pharmaceuticals Q1 2026 Investor Update Conference CallVECTIVBIO HOLDING AGEarnings Call TranscriptsThank you for standing by. My name is Liz, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Ironwood Pharmaceuticals First Quarter 2026 Investor Update Conference Call. Al
- 8mo agoVECTIronwood Pharmaceuticals Q4 and Full Year 2025 Investor Update Conference Call - VECTIVBIO HOLDING AGEarnings Call Transcriptsthank you for standing by my name is liz and i'll be your conference operator today at this time i'd like to welcome everyone to the ironwood pharmaceutical q4 and full year 2025 investor update conference call all lines
- 2y agoAPGEENGNNAMSNAMSW+2NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of DirectorsGlobeNewswireNAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
- 2y agoIMTXIRWDALDRVECTMemo Therapeutics AG appoints Paul Carter as ChairpersonGlobeNewswirePRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market
- 2y agoENGNNAMSNKTXPCRX+1enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of DirectorsBusiness WireenGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced
- 2y agoKRONMACKMXCTPHVS+4Vicore Expands and Strengthens its Board of DirectorsACCESS NewswireSTOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of
- 3y agoVECTAlentis Therapeutics Appoints Luca Santarelli as ChairpersonBusiness WireSantarelli is a Proven Leader with a Track Record of Building Successful Biotech Companies Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for organ fibrosis and
- 3y agoIRWDVECTIronwood and VectivBio Announce the Completion of the Tender Offer for VectivBio SharesBusiness WireIronwood Pharmaceuticals, Inc. ("Ironwood") (NASDAQ:IRWD), a GI-focused healthcare company, and VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a global clinical-stage biopharmaceutical company pioneering novel,
- 3y agoVECTVectivBio Extraordinary General Meeting of Shareholders Approved All ProposalsGlobeNewswireBASEL, Switzerland, June 26, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare
- 3y agoIRWDVECTIronwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBioBusiness WireIronwood Pharmaceuticals, Inc. ("Ironwood") (NASDAQ:IRWD), a GI-focused healthcare company, and VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a global clinical-stage biopharmaceutical company pioneering novel,
- 3y agoCIRHMPTUSXVECTMoore Kuehn Encourages VECT, USX, CIR, and HMPT Investors to Contact Law FirmGlobeNewswireNEW YORK, June 09, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoBACKEMBKRADIVECTMoore Kuehn Encourages VECT, EMBK, BACK, and RADI Investors to Contact Law FirmPR NewswireNEW YORK, May 31, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
- 3y agoIRWDVECTIronwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal DiseasesBusiness Wire- Transaction Advances Ironwood's Vision of Becoming the Leading GI Healthcare Company - - Adds apraglutide, Next Generation, Synthetic GLP-2 Analog in Phase 3 for Short Bowel Syndrome with Intestinal Failure
- 3y agoVECTVectivBio Publishes Invitation to the Annual General MeetingGlobeNewswireBASEL, Switzerland, May 10, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions,
- 3y agoVECTVectivBio Reports Full Year 2022 Financial Results and Provides Business UpdateGlobeNewswireContinued Strong Progress and Momentum Across Multiple Programs with Key Upcoming Data Milestones Beginning Q2 2023 STARS Phase 3 Program of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) to
- 3y agoVECTVectivBio to Report Full Year 2022 Financial Results and Provide Business Update on Wednesday, April 19, 2023GlobeNewswireBASEL, Switzerland, April 12, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare
- 3y agoVECTVectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in JapanGlobeNewswireBASEL, Switzerland, March 13, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare
- 3y agoFRBNNAMSVECTVectivBio Announces Results of Extraordinary General MeetingGlobeNewswireBASEL, Switzerland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare
- 3y agoVECTVectivBio Publishes Invitation to the Extraordinary General Meeting of ShareholdersGlobeNewswireBASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare
- 4y agoVECTVectivBio to Present at the 2022 Jefferies London Healthcare ConferenceGlobeNewswireBASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare
- 4y agoVECTVectivBio Announces Completion of Enrollment for Colon-In-Continuity (CIC) Cohort of STARS Pivotal Phase 3 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF)GlobeNewswire-Largest global Phase 3 study ever conducted in SBS-IF recruiting a total of 144 patients, stratified 50/50 for Stoma and CIC anatomical subtypes -First Phase 3 study to prospectively evaluate safety and efficacy of a
- 4y agoVECTVectivBio Announces Closing of $125 Million Underwritten Offering of Ordinary SharesGlobeNewswireBASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare
- 4y agoVECTVectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary SharesGlobeNewswireBASEL, Switzerland, Oct. 13, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare
- 4y agoVECTVectivBio Reports Positive Interim Clinical Data from STARS Nutrition, a Phase 2 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure Patients (SBS-IF) with Colon-In-Continuity (CIC)GlobeNewswire• Treatment with apraglutide resulted in an average 50% reduction in Parenteral Support (PS) volume at six months • 80% of patients were clinical responders (defined as a reduction in volume of PS of at least 20%)
- 4y agoVECTVectivBio Announces Date of Extraordinary General Meeting of ShareholdersGlobeNewswireBASEL, Switzerland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare
- 4y agoCINGCINGWVECTCingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business UpdateGlobeNewswire$5 Million of Non-Dilutive FinancingVeteran Biotech Executive Appointed to Board KANSAS CITY, Kan., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed
- 4y agoVECTVectivBio Announces Closing of $54 Million Aggregate FinancingGlobeNewswireBASEL, Switzerland, June 29, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announces it has closed each of
- 4y agoVECTVectivBio Announces Pricing of $30 Million Public Offering of Ordinary SharesGlobeNewswireBASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the pricing of a
- 4y agoVECTVectivBio Announces Launch of Public Offering of Ordinary SharesGlobeNewswireBASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the launch of a
- 4y agoVECTVectivBio Publishes Invitation to the Annual General MeetingGlobeNewswireBASEL, Switzerland, June 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the invitation t
- 4y agoVECTVectivBio Announces First Two Patients Dosed in Phase 2 STARGAZE Study of Apraglutide for the Treatment of Acute Graft-versus-Host DiseaseGlobeNewswire– Interim proof-of-concept data anticipated from STARGAZE in H1 2023 – First-in-class regenerative, non-immunosuppressive approach to treating acute Graft-versus-Host Disease – Second clinical indication under evaluation for apraglutide, demo
- 4y agoVECTVectivBio to Participate at the Bank of America 2022 Healthcare ConferenceGlobeNewswireBASEL, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santare
- 4y agoVECTVectivBio Appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic CommunicationsGlobeNewswireBASEL, Switzerland, April 21, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the appointment
- 4y agoVECTVectivBio Reports Full Year 2021 Financial Results and Provides Business UpdateGlobeNewswireSignificant Progress Across Multiple Programs with Key Upcoming Catalysts Beginning H2 2022 STARS Phase 3 Program of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) On-Track for Topline Results at End of 2023
- 4y agoVECTVectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key CatalystsGlobeNewswireExclusive License with Asahi Kasei Pharma to develop and commercialize Apraglutide in Japan includes $30 million upfront cash payment, eligibility for up to $170 million in development and commercial milestones and double-digit royalties on apraglutide
- 4y agoVECTVectivBio Presents New Clinical Data Supporting Apraglutide for Treatment of Short Bowel Syndrome with Intestinal Failure (SBS-IF) Patients Who Have Renal Dysfunction at the 2022 American Society of Parenteral and Enteral Nutrition ConferenceGlobeNewswire-- Apraglutide well-tolerated and does not require dose-adjustment in patients with severe renal disease -- -- Results demonstrate potential to reach 28% of SBS-IF patients with renal dysfunction who are underserved by currently available therapies --
- 4y agoVECTVectivBio Presents Preclinical Data Supporting Apraglutide for Treatment of Acute Graft-Versus-Host Disease at the 48th Annual Meeting of the European Society for Blood and Marrow TransplantationGlobeNewswire-- Apraglutide, a next-generation GLP-2 analog, protected against chemotherapy-induced gastrointestinal (GI) damage and improved survival in mouse models of GI acute graft-versus-host disease (aGVHD) -- -- Data support regenerative, non-immunosuppress
- 4y agoVECTVectivBio to Present at the SVB Leerink 11th Annual Global Healthcare ConferenceGlobeNewswireBASEL, Switzerland, Feb. 08, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santar
- 5y agoVECTVectivBio Announces Third Quarter 2021 Business UpdateGlobeNewswire-Pivotal STARS Program of Apraglutide in SBS-IF Progressing with Majority of Sites Activated and Screening; STARS Nutrition Interim Results Expected 1H 2022- -Expanded Rare Disease Pipeline with the Acquisition of CoMET Small Molecule Platform for
- 5y agoVECTVectivBio to Present at the Credit Suisse 30th Annual Healthcare ConferenceGlobeNewswireBASEL, Switzerland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santar
- 5y agoVECTVectivBio Announces Successful Opening of US IND for Apraglutide for Acute Graft-Versus-Host DiseaseGlobeNewswire-FDA clears IND Application for Apraglutide for Acute Graft-Versus-Host Disease - Dosing of first patient expected in 1Q 2022 - - Interim data anticipated in 2H 2022 - - FDA previously granted orphan drug designation for apraglutide for the prev
- 5y agoVECTVectivBio Announces Closing of Comet Therapeutics AcquisitionGlobeNewswireBASEL, Switzerland, Sept. 21, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the closing of
- 5y agoVECTVectivBio Announces Upcoming Investor EventsGlobeNewswireBASEL, Switzerland, Sept. 16, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced upcoming inves
- 5y agoVECTVectivBio Appoints Scott Applebaum as Chief Legal Officer & Corporate SecretaryGlobeNewswireBASEL, Switzerland, Sept. 08, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the appointment
- 5y agoVECTVectivBio Announces Results of Extraordinary General MeetingGlobeNewswireBASEL, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Paul R. Ca
- 5y agoVECTVectivBio to Acquire Comet Therapeutics and Host R&D DayGlobeNewswire- Acquisition of Innovative Small Molecule Platform Significantly Expands Rare Disease Pipeline -- VectivBio to Host R&D Day on September 21, 2021- BASEL, Switzerland, Aug. 31, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT
- 5y agoVECTVectivBio Publishes Invitation to the Extraordinary General MeetingGlobeNewswireBASEL, Switzerland, Aug. 12, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare cond
- 5y agoVECTVectivBio Nominates Paul R. Carter and Murray W. Stewart for Election to its Board of DirectorsGlobeNewswire- Industry veterans bring decades of clinical, regulatory and commercial management expertise to VectivBio - - Nominees will stand for election at an Extraordinary General Meeting of shareholders on September 2, 2021 - BASEL, Switzerland, July 12, 2